You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsocarboxazid
Accession NumberDB01247  (APRD00701)
TypeSmall Molecule
GroupsApproved
DescriptionAn MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)
Structure
Thumb
Synonyms
Isocarboxazida
Isocarboxazide
Isocarboxazidum
Marplan
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Marplantablet10 mg/1oralValidus Pharmaceuticals LLC1959-07-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EnerzerTakeda
IsocarboxazidAlliance
Brand mixturesNot Available
SaltsNot Available
Categories
UNII34237V843T
CAS number59-63-2
WeightAverage: 231.2505
Monoisotopic: 231.100776675
Chemical FormulaC12H13N3O2
InChI KeyInChIKey=XKFPYPQQHFEXRZ-UHFFFAOYSA-N
InChI
InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
IUPAC Name
N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
SMILES
CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylmethylamines
Direct ParentPhenylmethylamines
Alternative Parents
Substituents
  • Phenylmethylamine
  • Benzylamine
  • Heteroaromatic compound
  • Oxazole
  • Isoxazole
  • Azole
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationMay be used to treat major depressive disorder.
PharmacodynamicsIsocarboxazid is a non-selective hydrazine monoamine oxidase (MAO) inhibitor used to treat depression. In vivo and in vitro studies demonstrated inhibition of MAO in the brain, heart, and liver. Depression is a complicated disease that is not fully understood. It is thought that depression may be linked to an imbalance of chemicals within the brain. When depression occurs, there may be a decrease in the amount of chemicals released from nerve cells in the brain. These chemicals are called monoamines. Monoamines are broken down by a chemical called monoamine oxidase. Isocarboxazid prevents monoamine oxidase from breaking down the monoamines. This results in an increased amount of active monoamines in the brain. By increasing the amount of monoamines in the brain, the imbalance of chemicals thought to be caused by depression is altered. This helps relieve the symptoms of depression.
Mechanism of actionIsocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase–A (MAO-A) and monoamine oxidase–B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors.
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic and rapid (by oxidation).

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySigns of overdose include severe anxiety, confusion, convulsions, cool clammy skin, severe dizziness, severe drowsiness, fast and irregular pulse, fever, hallucinations, severe headache, high or low blood pressure, hyperactive reflexes, muscle stiffness, respiratory depression or failure, slowed reflexes, sweating, severe trouble in sleeping, and unusual irritability.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9783
Caco-2 permeable-0.5531
P-glycoprotein substrateNon-substrate0.6987
P-glycoprotein inhibitor INon-inhibitor0.9138
P-glycoprotein inhibitor IINon-inhibitor0.9716
Renal organic cation transporterNon-inhibitor0.8247
CYP450 2C9 substrateNon-substrate0.8471
CYP450 2D6 substrateNon-substrate0.8141
CYP450 3A4 substrateNon-substrate0.6057
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8885
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8518
Ames testAMES toxic0.5973
CarcinogenicityCarcinogens 0.5
BiodegradationNot ready biodegradable0.9227
Rat acute toxicity2.9486 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9209
hERG inhibition (predictor II)Non-inhibitor0.9069
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Prices
Unit descriptionCostUnit
Marplan 10 mg tablet3.45USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105-106 °CU.S. Patent 2,908,688.
water solubility1.6 mg/mL at 25 °CMEYLAN,WM et al. (1996)
logP1.49HANSCH,C ET AL. (1995)
pKa10.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.224 mg/mLALOGPS
logP1.19ALOGPS
logP1.43ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)12.02ChemAxon
pKa (Strongest Basic)3.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.16 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity74.78 m3·mol-1ChemAxon
Polarizability24.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-9500000000-6ab30f52fc69889b3fa2View in MoNA
References
Synthesis Reference

U.S. Patent 2,908,688.

General References
  1. Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE: A trial of isocarboxazid in the treatment of bulimia nervosa. J Clin Psychopharmacol. 1988 Dec;8(6):391-6. [PubMed:3069879 ]
External Links
ATC CodesN06AF01
AHFS CodesNot Available
PDB Entries
FDA labelDownload (56.5 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineIsocarboxazid may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineIsocarboxazid may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
AcarboseIsocarboxazid may increase the hypoglycemic activities of Acarbose.
AcebutololIsocarboxazid may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aceprometazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Acetophenazine.
AlbiglutideIsocarboxazid may increase the hypoglycemic activities of Albiglutide.
AliskirenIsocarboxazid may increase the hypotensive activities of Aliskiren.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Isocarboxazid.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Isocarboxazid.
AlogliptinIsocarboxazid may increase the hypoglycemic activities of Alogliptin.
AlprenololIsocarboxazid may increase the hypotensive activities of Alprenolol.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Isocarboxazid.
AmbrisentanIsocarboxazid may increase the hypotensive activities of Ambrisentan.
AmineptineIsocarboxazid may increase the serotonergic activities of Amineptine.
AmisulprideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amisulpride.
AmitriptylineIsocarboxazid may increase the serotonergic activities of Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Isocarboxazid.
AmlodipineIsocarboxazid may increase the hypotensive activities of Amlodipine.
AmoxapineIsocarboxazid may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Isocarboxazid.
AmperozideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amperozide.
AmphetamineIsocarboxazid may increase the hypertensive activities of Amphetamine.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Isocarboxazid.
ApraclonidineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Apraclonidine.
ArbutamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Arformoterol.
AripiprazoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aripiprazole.
AsenapineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Asenapine.
AtenololIsocarboxazid may increase the hypotensive activities of Atenolol.
AtomoxetineIsocarboxazid may increase the central neurotoxic activities of Atomoxetine.
AtropineIsocarboxazid may increase the hypertensive activities of Atropine.
AzaperoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Azaperone.
BambuterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bambuterol.
BenazeprilIsocarboxazid may increase the hypotensive activities of Benazepril.
BendroflumethiazideIsocarboxazid may increase the hypotensive activities of Bendroflumethiazide.
BenzphetamineIsocarboxazid may increase the hypertensive activities of Benzphetamine.
BepridilIsocarboxazid may increase the hypotensive activities of Bepridil.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Isocarboxazid.
BetaxololIsocarboxazid may increase the hypotensive activities of Betaxolol.
BethanidineIsocarboxazid may increase the hypotensive activities of Bethanidine.
BezafibrateThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bezafibrate.
BifeprunoxThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bifeprunox.
BimatoprostIsocarboxazid may increase the hypotensive activities of Bimatoprost.
BisoprololIsocarboxazid may increase the hypotensive activities of Bisoprolol.
BosentanIsocarboxazid may increase the hypotensive activities of Bosentan.
BretyliumIsocarboxazid may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Brexpiprazole.
BrimonidineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Brimonidine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isocarboxazid.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Isocarboxazid.
BupranololIsocarboxazid may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Isocarboxazid.
BupropionIsocarboxazid may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Isocarboxazid.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Isocarboxazid.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Isocarboxazid.
CanagliflozinIsocarboxazid may increase the hypoglycemic activities of Canagliflozin.
CandesartanIsocarboxazid may increase the hypotensive activities of Candesartan.
CandoxatrilIsocarboxazid may increase the hypotensive activities of Candoxatril.
CaptoprilIsocarboxazid may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Isocarboxazid.
CariprazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Cariprazine.
CarteololIsocarboxazid may increase the hypotensive activities of Carteolol.
CarvedilolIsocarboxazid may increase the hypotensive activities of Carvedilol.
CeliprololIsocarboxazid may increase the hypotensive activities of Celiprolol.
ChlorothiazideIsocarboxazid may increase the hypotensive activities of Chlorothiazide.
ChlorphentermineIsocarboxazid may increase the hypertensive activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorpromazine.
ChlorpropamideIsocarboxazid may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorprothixene.
ChlorthalidoneIsocarboxazid may increase the hypotensive activities of Chlorthalidone.
CilazaprilIsocarboxazid may increase the hypotensive activities of Cilazapril.
CirazolineIsocarboxazid may increase the hypertensive activities of Cirazoline.
CitalopramIsocarboxazid may increase the serotonergic activities of Citalopram.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Isocarboxazid.
ClemastineIsocarboxazid may increase the anticholinergic activities of Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clenbuterol.
ClomipramineIsocarboxazid may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isocarboxazid.
ClonidineIsocarboxazid may increase the hypotensive activities of Clonidine.
ClozapineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clozapine.
CryptenamineIsocarboxazid may increase the hypotensive activities of Cryptenamine.
CyamemazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Cyamemazine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Isocarboxazid.
CyclothiazideIsocarboxazid may increase the hypotensive activities of Cyclothiazide.
CyproheptadineIsocarboxazid may increase the anticholinergic activities of Cyproheptadine.
DapagliflozinIsocarboxazid may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Isocarboxazid.
DapoxetineIsocarboxazid may increase the serotonergic activities of Dapoxetine.
DebrisoquinIsocarboxazid may increase the hypotensive activities of Debrisoquin.
DeserpidineIsocarboxazid may increase the hypotensive activities of Deserpidine.
DesipramineIsocarboxazid may increase the serotonergic activities of Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Isocarboxazid.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Isocarboxazid.
DesvenlafaxineIsocarboxazid may increase the serotonergic activities of Desvenlafaxine.
DexmethylphenidateIsocarboxazid may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineIsocarboxazid may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanIsocarboxazid may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Isocarboxazid.
DiazoxideIsocarboxazid may increase the hypotensive activities of Diazoxide.
DiethylpropionIsocarboxazid may increase the hypertensive activities of Diethylpropion.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Isocarboxazid.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Isocarboxazid.
DiltiazemIsocarboxazid may increase the hypotensive activities of Diltiazem.
DipivefrinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dipivefrin.
DisopyramideIsocarboxazid may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dobutamine.
DolasetronDolasetron may increase the serotonergic activities of Isocarboxazid.
DomperidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Domperidone.
DorzolamideIsocarboxazid may increase the hypotensive activities of Dorzolamide.
DosulepinIsocarboxazid may increase the serotonergic activities of Dosulepin.
DoxapramIsocarboxazid may increase the hypertensive activities of Doxapram.
DoxazosinIsocarboxazid may increase the hypotensive activities of Doxazosin.
DoxepinIsocarboxazid may increase the serotonergic activities of Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Isocarboxazid.
DoxylamineIsocarboxazid may increase the anticholinergic activities of Doxylamine.
DroperidolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Droperidol.
DroxidopaThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Droxidopa.
DulaglutideIsocarboxazid may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Isocarboxazid.
DuloxetineIsocarboxazid may increase the serotonergic activities of Duloxetine.
EfonidipineIsocarboxazid may increase the hypotensive activities of Efonidipine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Isocarboxazid.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Isocarboxazid.
EmpagliflozinIsocarboxazid may increase the hypoglycemic activities of Empagliflozin.
EnalaprilIsocarboxazid may increase the hypotensive activities of Enalapril.
EnalaprilatIsocarboxazid may increase the hypotensive activities of Enalaprilat.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Isocarboxazid.
EphedraThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ephedra.
EpinephrineIsocarboxazid may increase the hypertensive activities of Epinephrine.
EpoprostenolIsocarboxazid may increase the hypotensive activities of Epoprostenol.
EprosartanIsocarboxazid may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Isocarboxazid.
ErgonovineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Isocarboxazid.
ErgotamineIsocarboxazid may increase the hypertensive activities of Ergotamine.
EscitalopramIsocarboxazid may increase the serotonergic activities of Escitalopram.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Isocarboxazid.
EsmirtazapineIsocarboxazid may increase the serotonergic activities of Esmirtazapine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Isocarboxazid.
EtoperidoneIsocarboxazid may increase the serotonergic activities of Etoperidone.
ExenatideIsocarboxazid may increase the hypoglycemic activities of Exenatide.
FelodipineIsocarboxazid may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fencamfamine.
FenfluramineIsocarboxazid may increase the serotonergic activities of Fenfluramine.
FenoldopamIsocarboxazid may increase the hypotensive activities of Fenoldopam.
FenoterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Isocarboxazid.
FluoxetineIsocarboxazid may increase the serotonergic activities of Fluoxetine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Isocarboxazid.
FlupentixolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluspirilene.
FluvoxamineIsocarboxazid may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Isocarboxazid.
FormoterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Formoterol.
FosinoprilIsocarboxazid may increase the hypotensive activities of Fosinopril.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Isocarboxazid.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Isocarboxazid.
GliclazideIsocarboxazid may increase the hypoglycemic activities of Gliclazide.
GlimepirideIsocarboxazid may increase the hypoglycemic activities of Glimepiride.
GlipizideIsocarboxazid may increase the hypoglycemic activities of Glipizide.
GlyburideIsocarboxazid may increase the hypoglycemic activities of Glyburide.
GranisetronGranisetron may increase the serotonergic activities of Isocarboxazid.
GuanabenzIsocarboxazid may increase the hypotensive activities of Guanabenz.
GuanadrelIsocarboxazid may increase the hypotensive activities of Guanadrel.
GuanethidineIsocarboxazid may increase the hypotensive activities of Guanethidine.
GuanfacineIsocarboxazid may increase the hypotensive activities of Guanfacine.
HaloperidolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Haloperidol.
HexamethoniumIsocarboxazid may increase the hypotensive activities of Hexamethonium.
HydralazineIsocarboxazid may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideIsocarboxazid may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hydrocodone.
HydroflumethiazideIsocarboxazid may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideIsocarboxazid may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
IloperidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Iloperidone.
ImipramineIsocarboxazid may increase the serotonergic activities of Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isocarboxazid.
IndacaterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Indacaterol.
IndalpineIsocarboxazid may increase the serotonergic activities of Indalpine.
IndapamideIsocarboxazid may increase the hypotensive activities of Indapamide.
IndenololIsocarboxazid may increase the hypotensive activities of Indenolol.
IndoraminIsocarboxazid may increase the hypotensive activities of Indoramin.
Insulin AspartIsocarboxazid may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirIsocarboxazid may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineIsocarboxazid may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineIsocarboxazid may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanIsocarboxazid may increase the hypoglycemic activities of Insulin Human.
Insulin LisproIsocarboxazid may increase the hypoglycemic activities of Insulin Lispro.
IrbesartanIsocarboxazid may increase the hypotensive activities of Irbesartan.
IsoetarineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoetarine.
IsomethepteneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoprenaline.
IsradipineIsocarboxazid may increase the hypotensive activities of Isradipine.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Isocarboxazid.
LabetalolIsocarboxazid may increase the hypotensive activities of Labetalol.
LacidipineIsocarboxazid may increase the hypotensive activities of Lacidipine.
LanreotideIsocarboxazid may increase the hypoglycemic activities of Lanreotide.
LatanoprostIsocarboxazid may increase the hypotensive activities of Latanoprost.
LercanidipineIsocarboxazid may increase the hypotensive activities of Lercanidipine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Isocarboxazid.
LevomilnacipranIsocarboxazid may increase the serotonergic activities of Levomilnacipran.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Isocarboxazid.
LevonordefrinIsocarboxazid may increase the hypertensive activities of Levonordefrin.
LinezolidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Linezolid.
LiraglutideIsocarboxazid may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineIsocarboxazid may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilIsocarboxazid may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Isocarboxazid.
LithiumThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lithium.
LofexidineIsocarboxazid may increase the hypotensive activities of Lofexidine.
LorcaserinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lorcaserin.
LosartanIsocarboxazid may increase the hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Loxapine.
Lu AA21004Isocarboxazid may increase the serotonergic activities of Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lurasidone.
MacitentanIsocarboxazid may increase the hypotensive activities of Macitentan.
ManidipineIsocarboxazid may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Isocarboxazid.
MecamylamineIsocarboxazid may increase the hypotensive activities of Mecamylamine.
MecaserminIsocarboxazid may increase the hypoglycemic activities of Mecasermin.
MelperoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Melperone.
MephentermineIsocarboxazid may increase the hypertensive activities of Mephentermine.
MequitazineIsocarboxazid may increase the anticholinergic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mesoridazine.
MetaraminolIsocarboxazid may increase the hypertensive activities of Metaraminol.
MetforminIsocarboxazid may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methadone.
MethamphetamineIsocarboxazid may increase the hypertensive activities of Methamphetamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methotrimeprazine.
MethoxamineIsocarboxazid may increase the hypertensive activities of Methoxamine.
MethyldopaThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methyldopa.
Methylene blueIsocarboxazid may increase the serotonergic activities of Methylene blue.
MethylphenidateIsocarboxazid may increase the hypertensive activities of Methylphenidate.
MetipranololIsocarboxazid may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Metoclopramide.
MetolazoneIsocarboxazid may increase the hypotensive activities of Metolazone.
MetoprololIsocarboxazid may increase the hypotensive activities of Metoprolol.
MianserinIsocarboxazid may increase the neurotoxic activities of Mianserin.
MibefradilIsocarboxazid may increase the hypotensive activities of Mibefradil.
MidodrineIsocarboxazid may increase the hypertensive activities of Midodrine.
MifepristoneIsocarboxazid may increase the hypoglycemic activities of Mifepristone.
MiglitolIsocarboxazid may increase the hypoglycemic activities of Miglitol.
MilnacipranIsocarboxazid may increase the serotonergic activities of Milnacipran.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Isocarboxazid.
MinoxidilIsocarboxazid may increase the hypotensive activities of Minoxidil.
MirtazapineIsocarboxazid may increase the central neurotoxic activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Isocarboxazid.
MoclobemideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Moclobemide.
MoexiprilIsocarboxazid may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Morphine.
MoxonidineIsocarboxazid may increase the hypotensive activities of Moxonidine.
NadololIsocarboxazid may increase the hypotensive activities of Nadolol.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Isocarboxazid.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Isocarboxazid.
NateglinideIsocarboxazid may increase the hypoglycemic activities of Nateglinide.
NebivololIsocarboxazid may increase the hypotensive activities of Nebivolol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Isocarboxazid.
NicardipineIsocarboxazid may increase the hypotensive activities of Nicardipine.
NicorandilIsocarboxazid may increase the hypotensive activities of Nicorandil.
NiguldipineIsocarboxazid may increase the hypotensive activities of Niguldipine.
NilvadipineIsocarboxazid may increase the hypotensive activities of Nilvadipine.
NimodipineIsocarboxazid may increase the hypotensive activities of Nimodipine.
NisoldipineIsocarboxazid may increase the hypotensive activities of Nisoldipine.
NitrendipineIsocarboxazid may increase the hypotensive activities of Nitrendipine.
NitroprussideIsocarboxazid may increase the hypotensive activities of Nitroprusside.
NorepinephrineIsocarboxazid may increase the hypertensive activities of Norepinephrine.
NortriptylineIsocarboxazid may increase the serotonergic activities of Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Isocarboxazid.
OctreotideIsocarboxazid may increase the hypoglycemic activities of Octreotide.
OlanzapineIsocarboxazid may increase the serotonergic activities of Olanzapine.
OlmesartanIsocarboxazid may increase the hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Olodaterol.
OmapatrilatIsocarboxazid may increase the hypotensive activities of Omapatrilat.
OndansetronThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Isocarboxazid.
OrciprenalineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Orciprenaline.
OsanetantThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Osanetant.
OxprenololIsocarboxazid may increase the hypotensive activities of Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Isocarboxazid.
PaliperidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Isocarboxazid.
PargylineIsocarboxazid may increase the hypotensive activities of Pargyline.
ParoxetineIsocarboxazid may increase the serotonergic activities of Paroxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Isocarboxazid.
PasireotideIsocarboxazid may increase the hypoglycemic activities of Pasireotide.
PenbutololIsocarboxazid may increase the hypotensive activities of Penbutolol.
PentamidineIsocarboxazid may increase the hypoglycemic activities of Pentamidine.
PentoliniumIsocarboxazid may increase the hypotensive activities of Pentolinium.
PergolideThe metabolism of Pergolide can be decreased when combined with Isocarboxazid.
PerindoprilIsocarboxazid may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Perphenazine.
PethidineIsocarboxazid may increase the serotonergic activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Isocarboxazid.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isocarboxazid.
PhenoxybenzamineIsocarboxazid may increase the hypotensive activities of Phenoxybenzamine.
PhentermineIsocarboxazid may increase the hypertensive activities of Phentermine.
PhentolamineIsocarboxazid may increase the hypotensive activities of Phentolamine.
PhenylephrineIsocarboxazid may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Phenylpropanolamine.
PholcodinePholcodine may increase the serotonergic activities of Isocarboxazid.
PimozideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pimozide.
PinacidilIsocarboxazid may increase the hypotensive activities of Pinacidil.
PindololIsocarboxazid may increase the hypotensive activities of Pindolol.
PioglitazoneIsocarboxazid may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pirbuterol.
PizotifenIsocarboxazid may increase the anticholinergic activities of Pizotifen.
PolythiazideIsocarboxazid may increase the hypotensive activities of Polythiazide.
PramlintideIsocarboxazid may increase the hypoglycemic activities of Pramlintide.
PrazosinIsocarboxazid may increase the hypotensive activities of Prazosin.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Isocarboxazid.
ProcaterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Isocarboxazid.
PropericiazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Propericiazine.
PropranololIsocarboxazid may increase the hypotensive activities of Propranolol.
ProtriptylineIsocarboxazid may increase the serotonergic activities of Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isocarboxazid.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Isocarboxazid.
QuetiapineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Quetiapine.
QuinaprilIsocarboxazid may increase the hypotensive activities of Quinapril.
QuinineIsocarboxazid may increase the hypoglycemic activities of Quinine.
RamiprilIsocarboxazid may increase the hypotensive activities of Ramipril.
RasagilineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Rasagiline.
RemikirenIsocarboxazid may increase the hypotensive activities of Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Remoxipride.
RepaglinideIsocarboxazid may increase the hypoglycemic activities of Repaglinide.
RescinnamineIsocarboxazid may increase the hypotensive activities of Rescinnamine.
ReserpineIsocarboxazid may increase the hypotensive activities of Reserpine.
RiociguatIsocarboxazid may increase the hypotensive activities of Riociguat.
RisperidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Risperidone.
RitodrineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ritodrine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Isocarboxazid.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Isocarboxazid.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Isocarboxazid.
RosiglitazoneIsocarboxazid may increase the hypoglycemic activities of Rosiglitazone.
SalbutamolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salmeterol.
SaprisartanIsocarboxazid may increase the hypotensive activities of Saprisartan.
SaxagliptinIsocarboxazid may increase the hypoglycemic activities of Saxagliptin.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Isocarboxazid.
SelexipagIsocarboxazid may increase the hypotensive activities of Selexipag.
SertindoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sertindole.
SertralineIsocarboxazid may increase the serotonergic activities of Sertraline.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Isocarboxazid.
SitagliptinIsocarboxazid may increase the hypoglycemic activities of Sitagliptin.
SitaxentanIsocarboxazid may increase the hypotensive activities of Sitaxentan.
SpiraprilIsocarboxazid may increase the hypotensive activities of Spirapril.
SulfadiazineIsocarboxazid may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleIsocarboxazid may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleIsocarboxazid may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Isocarboxazid.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Isocarboxazid.
SunitinibIsocarboxazid may increase the hypoglycemic activities of Sunitinib.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Isocarboxazid.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Isocarboxazid.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tedizolid Phosphate.
TelmisartanIsocarboxazid may increase the hypotensive activities of Telmisartan.
TemocaprilIsocarboxazid may increase the hypotensive activities of Temocapril.
TerbutalineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terbutaline.
TerlipressinIsocarboxazid may increase the hypotensive activities of Terlipressin.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Isocarboxazid.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Isocarboxazid.
TetryzolineIsocarboxazid may increase the hypertensive activities of Tetryzoline.
ThioproperazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thiothixene.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Isocarboxazid.
TianeptineIsocarboxazid may increase the serotonergic activities of Tianeptine.
TiboloneIsocarboxazid may increase the hypotensive activities of Tibolone.
TicrynafenIsocarboxazid may increase the hypotensive activities of Ticrynafen.
TimololIsocarboxazid may increase the hypotensive activities of Timolol.
TolazamideIsocarboxazid may increase the hypoglycemic activities of Tolazamide.
TolazolineIsocarboxazid may increase the hypotensive activities of Tolazoline.
TolbutamideIsocarboxazid may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isocarboxazid.
TorasemideIsocarboxazid may increase the hypotensive activities of Torasemide.
TramadolTramadol may increase the neuroexcitatory activities of Isocarboxazid.
TramadolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tramadol.
TrandolaprilIsocarboxazid may increase the hypotensive activities of Trandolapril.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isocarboxazid.
TravoprostIsocarboxazid may increase the hypotensive activities of Travoprost.
TrazodoneIsocarboxazid may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Isocarboxazid.
TreprostinilIsocarboxazid may increase the hypotensive activities of Treprostinil.
TrichlormethiazideIsocarboxazid may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Triflupromazine.
TrimazosinIsocarboxazid may increase the hypotensive activities of Trimazosin.
TrimethaphanIsocarboxazid may increase the hypotensive activities of Trimethaphan.
TrimipramineIsocarboxazid may increase the serotonergic activities of Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Isocarboxazid.
UnoprostoneIsocarboxazid may increase the hypotensive activities of Unoprostone.
ValsartanIsocarboxazid may increase the hypotensive activities of Valsartan.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Isocarboxazid.
VenlafaxineIsocarboxazid may increase the serotonergic activities of Venlafaxine.
VilanterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Vilanterol.
VilazodoneIsocarboxazid may increase the serotonergic activities of Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Isocarboxazid.
VortioxetineIsocarboxazid may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Isocarboxazid.
XylometazolineIsocarboxazid may increase the hypotensive activities of Xylometazoline.
ZimelidineIsocarboxazid may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Isocarboxazid.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Isocarboxazid.
ZotepineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals, avoid tyramine, caffeine and alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Thase ME, Trivedi MH, Rush AJ: MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219. [PubMed:7612154 ]
  3. Kettler R, Da Prada M, Burkard WP: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl. 1990;360:101-2. [PubMed:2248058 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Mason ST: Chronic administration of type A monoamine oxidase inhibitors increases duration of thiopentone anaesthesia in the rat. Physiol Behav. 1985 Aug;35(2):201-3. [PubMed:4070383 ]
  2. Kettler R, Da Prada M, Burkard WP: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl. 1990;360:101-2. [PubMed:2248058 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23